Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F14%3A43914658" target="_blank" >RIV/00023752:_____/14:43914658 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.psychiatrist.com/JCP/article/Pages/2014/v75n04/v75n0411.aspx" target="_blank" >http://www.psychiatrist.com/JCP/article/Pages/2014/v75n04/v75n0411.aspx</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4088/JCP.13m08433" target="_blank" >10.4088/JCP.13m08433</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study

Popis výsledku v původním jazyce

Agomelatine was efficacious in reducing symptoms in a short-term placebo-controlled trial in GAD and in preventing relapse in a longer term placebo-controlled study. An additional short-term placebo-controlled study is required by regulatory agencies toconfirm the efficacy of agomelatine in GAD. This 12-week, placebo-controlled, double-blind, randomized, parallel group, international, multicenter study was designed to confirm the efficacy of agomelatine 25-50 mg/d in the treatment of patients with a primary DSM-IV-TR diagnosis of GAD. The primary outcome measure was the (HARS) total score. Assay sensitivity was evaluated by including an escitalopram (10-20 mg/d) group. The study was undertaken in 45 clinical centers from April 2010 to July 2011. One hundred thirty-nine outpatients were included in the agomelatine group, 131 in the placebo group, and 142 in the escitalopram group. Agomelatine significantly reduced mean (SD) HARS total score (agomelatine-placebo difference: 4.71 [1.03],

Název v anglickém jazyce

Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study

Popis výsledku anglicky

Agomelatine was efficacious in reducing symptoms in a short-term placebo-controlled trial in GAD and in preventing relapse in a longer term placebo-controlled study. An additional short-term placebo-controlled study is required by regulatory agencies toconfirm the efficacy of agomelatine in GAD. This 12-week, placebo-controlled, double-blind, randomized, parallel group, international, multicenter study was designed to confirm the efficacy of agomelatine 25-50 mg/d in the treatment of patients with a primary DSM-IV-TR diagnosis of GAD. The primary outcome measure was the (HARS) total score. Assay sensitivity was evaluated by including an escitalopram (10-20 mg/d) group. The study was undertaken in 45 clinical centers from April 2010 to July 2011. One hundred thirty-nine outpatients were included in the agomelatine group, 131 in the placebo group, and 142 in the escitalopram group. Agomelatine significantly reduced mean (SD) HARS total score (agomelatine-placebo difference: 4.71 [1.03],

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FL - Psychiatrie, sexuologie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Clinical Psychiatry

ISSN

0160-6689

e-ISSN

—

Svazek periodika

75

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

362-368

Kód UT WoS článku

000336525700011

EID výsledku v databázi Scopus

—